Because of the selectivity of TRAIL towards cancer cells, there has been significant interest in developing agents targeting TRAIL or DR5 for cancer therapy, including recombinant protein, agonistic antibodies and small molecules [3, 4]. Here, TNFRSF10B is linked to cancer.